Newsfeeds - Spark Newswire

3 minute read

Legal
News

U.S. District Court Dismisses AIM’s “Baseless” Section 13(d) Claim; Court Rules That Allowing Claim To Proceed Would Be Inconsistent With Statutory

Today, 5:41 AM

Court Rules that Allowing Claim to Proceed Would be Inconsistent with Statutory Purpose of Investor Protection AIM's Stock Price Continues Dramatic Decline, Closing at New 52-Week Low of $0.479 on October

AIM

30 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 5:41 AM

During Wednesday's trading, 517 companies set new 52-week lows.

$APE

3 minute read

AIM ImmunoTech Announces FDA Clearance Of IND Application To Evaluate Ampligen In Phase 2 Clinical Study For The Treatment Of Post-COVID Conditions

By Benzinga Newsdesk

Today, 5:41 AM

AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune

AIM

28 minute read

Options

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

Today, 5:41 AM

During Monday's trading, 528 companies set new 52-week lows.

$APE

2 minute read

Earnings

Looking Into AIM ImmunoTech’s Return On Capital Employed

By Benzinga Insights

Today, 5:41 AM

AIM ImmunoTech (AMEX:AIM) brought in sales totaling $30 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 26.99%, resulting in a loss of $4.85 million.

AIM

3 minute read

Why Splunk Is Trading Lower By Around 10%; Here Are 28 Stocks Moving Premarket

By Lisa Levin

Today, 5:41 AM

Gainers ECMOHO Limited (NASDAQ: MOHO) shares rose 47% to $0.2149 in pre-market trading.

ADSK

1 minute read

FDA
News

AIM Immunotech Announces Commencement Of Phase 2 Study Of Ampligen For The Treatment Of Pancreatic Cancer

By Benzinga Newsdesk

Today, 5:41 AM

AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune

AIM

1 minute read

Earnings

Recap: AIM ImmunoTech Q2 Earnings

By Benzinga Insights

Today, 5:41 AM

AIM ImmunoTech (AMEX:AIM) reported its Q2 earnings results on Monday, August 15, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

AIM

1 minute read

AIM ImmunoTech Q2 EPS $(0.10) Up From $(0.12) YoY

By Bill Haddad

Today, 5:41 AM

AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.10) per share. This is a 16.67 percent increase over losses of $(0.12) per share from the same period last year.

AIM

2 minute read

Earnings

Earnings Scheduled For August 12, 2022

By Benzinga Insights

Today, 5:41 AM

Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million.

AIM